REMS
S. aureus
infections.Spectrum:
Absorption: Well absorbed following oral administration.
Distribution: Widely distributed; enters CSF.
Protein Binding: 80%.
Half-Life: 3 hr.
Contraindicated in:
Use Cautiously in:
Derm: ACUTE GENERALIZED EXANTHEMATOUS PUSTULOSIS, DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), pruritus, rash, STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS
EENT: red discoloration of tears
GI: abdominal pain, diarrhea, flatulence, heartburn, nausea, vomiting, HEPATOTOXICITY, red discoloration of saliva and teeth
GU: red discoloration of urine
Hemat: bleeding, hemolytic anemia, thrombocytopenia, THROMBOTIC MICROANGIOPATHY (INCLUDING THROMBOTIC THROMBOCYTOPENIC PURPURA AND HEMOLYTIC UREMIA SYNDROME)
MS: arthralgia, muscle weakness, myalgia
Neuro: ataxia, confusion, drowsiness, fatigue, headache, weakness
Resp: INTERSTITIAL LUNG DISEASE
Misc: flu-like syndrome, HYPERSENSITIVITY REACTIONS (INCLUDING ANGIOEDEMA)
Drug-drug:
Tuberculosis
Asymptomatic Carriers of Meningococcus
H. influenzae Prophylaxis
Synergy for S. aureus Infections
Lab Test Considerations:
IV Administration:
H. influenzae
type B infection. Prophylactic course is usually short term.